Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 1995, known as the PSLRA. These include statements regarding management's intention, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. Forwar ...

Company Strategy & Portfolio - Whitehawk Therapeutics is transitioning into an ADC-focused company, leveraging advanced ADC technology and targeting significant patient populations[6, 7] - The company's portfolio includes three assets (HWK-007, HWK-016, and HWK-206) rapidly progressing to clinical trials, with all three INDs anticipated in the next 15 months[7, 9] - Whitehawk's ADC platform is engineered for minimal off-target toxicity, greater stability, and a higher therapeutic index[9, 12] ADC Technology & Efficacy - Whitehawk utilizes a proprietary TOPO1 inhibitor payload and a highly stable, cleavable linker to improve the therapeutic index of its ADCs[13] - Switching to an advanced ADC platform technology delivers efficacy gains compared to 1st generation ADCs, as demonstrated by increased Overall Response Rates (ORR) in various cancer indications[17] - For example, in SEZ6 targeting for Small Cell Lung Cancer (SCLC), next-wave ADCs like ABBV-706 achieved a 61% ORR, compared to 19% with 1st generation ADCs[17] Target & Clinical Development - HWK-007 targets PTK7, which is overexpressed in a broad spectrum of cancers, including Non-Small Cell Lung Cancer (NSCLC) and Ovarian cancer, with potential to outperform current ADC benchmarks[20, 29, 31] - HWK-016 targets MUC16, a glycoprotein overexpressed in cancers affecting women, with a Phase 1 trial planned in ovarian cancer[40, 50] - HWK-206 targets SEZ6, a CNS protein upregulated in tumors of neuroendocrine origin, with a Phase 1 trial planned in SCLC and Neuroendocrine Neoplasms (NENs)[55, 65] Financial Outlook - The company's cash runway is expected to fund operations into 2028, including anticipated key clinical data[3, 67]